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0014-5793  2012 Federation of European BiochemicGuanylyl cyclase C (GC-C) is predominantly expressed in intestinal epithelial cells and serves as the
receptor for the gastrointestinal hormones guanylin and uroguanylin, and the heat-stable entero-
toxin, the causative agent for Travellers’ Diarrhea. Activation of GC-C results in an increase in intra-
cellular levels of cGMP, which can regulate ﬂuid and ion secretion, colon cell proliferation, and the
gut immune system. This review highlights recent ﬁndings arising from studies in the GC-C knock-
out mouse, along with enigmatic results obtained from the ﬁrst descriptions of human disease
caused by mutations in the GC-C gene. We provide some insight into these new ﬁndings and com-
ment on areas of future study, which may enhance our knowledge of this evolutionarily conserved
receptor and signaling system.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
The importance of intestinal health has been recognized for
over 2000 years, most famously by Hippocrates who said, ‘‘All dis-
ease begins in the gut’’. Although not every disease may initiate in
the intestine, overall human health and well-being is strongly
dependent on the integrity of the gastrointestinal (GI) tract. The
GI tract is the largest organ-system in the body, and is responsible
for the ingestion, digestion and assimilation of food for the survival
of the organism. In this process the digestive system also has to
adapt to a large number of microbes that are ingested with the
food and colonize the intestine [1]. There are several defence strat-
egies employed by the GI tract to achieve this, which include the
secretion of antibodies in the mouth [2], the acidic pH in the stom-
ach, and cellular defence mechanisms that operate within the
intestine [3].
The intestine is the major site of digestion and absorption of
nutrients. Therefore, to enhance the surface area and thus the
absorptive capacity, intestinal villi form ﬁnger-like projections into
the lumen of the intestine. The villi are separated from each other
by crypts [4]. Epithelial cells that line the intestine are primarily
comprised of enterocytes which are absorptive in function [5].
The enterocytes are polarized whereby the cell membrane is dis-
tinctly sectioned into an apical and basolateral region, separated
by tight junctions. Other specialized cells present in the GI tract in-GA09, Department of Molec-
Institute of Science, Banga-
isweswariah).
al Societies. Published by Elsevierclude goblet cells which secrete mucous and other glycoproteins,
the enteroendocrine cells which secrete hormones, the dendritic
cells which are antigen presenting cells, the M-cells or microfold
cells which are responsible for antigen sampling, and the Paneth
cells, which are found in the crypts and produce antibacterial pep-
tides [3]. Located at the base of the crypt are the intestinal stem
cells that provide daughter transit amplifying cells that ultimately
form all the differentiated cells of the intestine [6]. The epithelial
layer of cells is protected from the contents of the lumen by a thick
mucosal layer made up of glycoproteins and mucins, which can
contain antibodies and antimicrobial peptides.
The human gut is a rich source of nutrition and plays host to a
variety of microbes that co-exist with a mutual dependence called
commensalism. The microbiome is comprised mainly of bacteria
[3], some protozoans [7] and even fungi [8]. They contribute to
host nutrition by producing enzymes that breakdown complex
polysaccharides for efﬁcient digestion of ingested food, and by pro-
ducing metabolites such as vitamins [9]. These microbes do not
disrupt the normal physiology of the body and their numbers are
kept in check by basal immune activity, which is stimulated by fac-
tors such as peptidoglycans from the bacterial cell wall [10]. Ge-
netic variation in humans give rise to differences in their
immune system, which then reﬂects in the composition of the mic-
robiota, and these differences are being correlated to the suscepti-
bility of the individual to immune-related diseases such as asthma
and intestinal inﬂammation [3].
The balance and composition of the gut microﬂora can be al-
tered by the use of antibiotics or by colonization of the intestine
by pathogens. This change may also induce, or be induced by,
modiﬁcations in the body’s immune response, ultimately leadingB.V. Open access under CC BY-NC-ND license.
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can frequently lead to inﬂammation and invasion of the epithelial
layer, diarrhea and poor nutrient absorption [11,12].
This review will focus on a member of the receptor guanylyl cy-
clase family of proteins, GC-C, in regulating intestinal function.
While it was realized many years ago that GC-C was the target of
a family of bacterial heat-stable enterotoxins that caused watery
diarrhea in humans and animals [13], recent information has high-
lighted the role of GC-C and cGMP in maintaining intestinal
homeostasis [14,15]. Aspects of GC-C structure have been de-
scribed in a comprehensive review that has been published re-
cently [16], and we will therefore not dwell on this in the
current review. Instead, we will highlight recent ﬁndings arising
from genetic approaches using mice, as well as evidence from hu-
man populations, that indicate the important roles that GC-C and
cGMP have to play in intestinal physiology.
2. Guanylyl cyclase C, intestinal ﬂuid secretion and feeding
behavior
Diarrhea was initially considered a primitive mechanism by
which the host attempts to ‘ﬂush out’ infectious agents, but it is
now appreciated that microbes disrupt the host’s secretory and
absorptive machinery in an attempt to be successfully transmitted.
There are various mechanisms by which microbes and their prod-
ucts cause diarrhea, and include direct lysis of epithelial cells, pro-
duction of pore forming toxins, or by manipulation of host
signaling pathways via second messengers such as cyclic AMP, cyc-
lic GMP and calcium ions [17].
The enterotoxigenic Escherichia coli or ETEC adhere to the intes-
tine and produce two types of toxins, the heat- labile (LT) and the
heat-stable enterotoxins (ST). The LT shares 82% amino acid homol-
ogy to cholera toxin, binds to the GM1 ganglioside andmediates the
onset of diarrhea in a manner similar to that of cholera toxin, via
elevation of intracellular cAMP [18]. ST is an 18-amino acid long
peptide with three disulﬁde bridges, and causes an increase in
chloride ion secretion, leading to secretory diarrhea [13]. The ST
receptor is guanylyl cyclase C [19]. GC-C is a multi-domain protein,
and a member of the receptor guanylyl cyclase family. GC-C is pri-
marily expressed in intestinal epithelial cells, and binds to the
endogenous gastrointestinal hormones guanylin and uroguanylin
[20–22]. Binding of guanylin or uroguanylin to GC-C results in
receptor activation, catalyzing the production of cGMP (Fig. 1). Cyc-
lic GMP can activate cGMP-dependent protein kinase II (PKGII), or
inhibit the activity of a cAMP-speciﬁc phosphodiesterase, PDE3,
thereby cross-activating cAMP–dependent protein kinase (PKA).
PKGII and PKA phosphorylate the cystic ﬁbrosis transmembrane
conductance regulator or CFTR, increasing its chloride-secreting
activity [23].
A marked reduction in Na+ absorption, and consequently de-
creased ﬂuid uptake by the intestinal cell, is also brought about
by ST and the guanylin family peptides [24]. This is mediated by
inhibition of the sodium-hydrogen exchanger, NHE3, following
its interaction with PKGII and the scaffolding protein NHERF2
[25]. In addition, cGMP enhances duodenal bicarbonate secretion
through an unknown channel [26]. Cyclic GMP can also directly
activate cyclic nucleotide gated channels (CNGs), leading to Ca2+
inﬂux [27] (Fig. 1).
GC-C signaling is terminated by hydrolysis of cGMP to GMP by a
cGMP-dependent phosphodiesterase, PDE5 [16]. Secretion of water
into the intestinal lumen is necessary for the lubrication and break-
down of the bolus of food, and this ﬂuid secretion is regulated by the
endogenous ligands of GC-C, guanylin and uroguanylin [21,28]. ST is
a super-agonist of GC-C, and induces abnormally high levels of
intracellular cGMP which causes aberrant ﬂuid-ion efﬂux, leadingto diarrhea. This disease is usually self-limiting in adults and symp-
toms resolvewithin a fewdays, therefore no speciﬁc treatment is re-
quired except oral rehydration. However, the incidence of mortality
in children can be very high [17].
Given the role that activation of GC-C has in stimulating ﬂuid
secretion in the intestine, attempts have been made to exploit this
pathway to relieve symptoms of chronic constipation. Currently,
an orally administered synthetic ST mimic, linaclotide [29], has
been successfully shown to alleviate constipation [30], and this
drug is currently awaiting FDA approval.
The mechanism of ST-induced diarrhea is unique in that it is the
only example where the primary target of a diarrheal disease-caus-
ing agent is a receptor directly controlling intestinal ﬂuid-ion
homeostasis. GC-C is well conserved from Pisces to Mammalia
and given its function and exploitation by microbes to cause a dis-
ease, it was anticipated that the receptor was conserved because of
its importance in intestinal physiology [16]. Two independent
groups generated knock-out mice for GUCY2C, the gene encoding
GC-C. Surprisingly, the GC-C knock-out mouse showed no abnor-
malities in the gut that could be associated with luminal dehydra-
tion, but were found to be resistant to ST-induced diarrhea [31,32].
This appeared to be paradoxical for a receptor so well conserved
evolutionarily, suggesting that the critical role(s) of GC-C would
become apparent when animals were subjected to stresses not
normally encountered in the restricted environment in which
these knock-out mice were bred.
It is worth mentioning at this stage that extra-intestinal roles
for GC-C, speciﬁcally in the nervous system, emerged on studies
with the knock-out mouse, and warrant a brief summary. Hyper-
phagia, obesity and metabolic syndrome were observed in GC-C
knock-out mice, and these functions appeared to be controlled by
circulating levels of uroguanylin, and neuronally-expressed GC-C
[33]. This ﬁnding was the ﬁrst report of speciﬁc extra-intestinal
roles for both GC-C and uroguanylin, highlighting the endocrine
function of uroguanylin, which is primarily synthesized in the
intestine and acts on intestinal GC-C in a paracrine manner [34].
A second example for the role of GC-C in the nervous systemwas
reported by Gong et al. [35]. Midbrain dopamine neurons express
GC-C, and on activation enhance excitatory responses mediated
by glutamate and acetylcholine in a cGMP and PKG-dependent
manner. GC-C knock-out mice demonstrated attention deﬁciency
and hyperactive behavior, which was reversed on administration
of a PKG activator.
GC-C, guanylin and uroguanylin are expressed in reproductive
tissues of the rat [36], though no role for this signaling pathway
has been described in these tissues. Perhaps subtle roles for this sig-
naling axis, in controlling fertility and reproduction may become
evident in the future through studies on the GC-C knock-outmouse.
3. Role of GC-C and cGMP in colon cancer cell cytostasis
The intestinal epithelium undergoes homeostatic cycles of pro-
liferation, migration, differentiation and apoptosis, driven by mul-
tipotent stem cells. An imbalance between cell proliferation and
apoptosis can therefore lead to the formation of tumours within
the gastrointestinal tract. Some years ago, it was noted that there
appeared to be an inverse correlation between the incidence of
colorectal cancer and secretory diarrhea caused by ETEC [37], lead-
ing to the hypothesis that activated GC-C could act as an anti-pro-
liferative agent in the intestine. Studies on both colorectal cell lines
[38] as well as GC-C knock-out mice [39] indicated that GC-C ex-
erts a cytostatic effect on epithelial cells following ligand-mediated
activation. This induction of colon cell cytostasis was mediated by
the regulation of calcium ion inﬂux via a cyclic nucleotide gated
channel, and was mimicked by analogs of cGMP [27,40,41].
Fig. 1. Signalling mechanisms mediated by GC-C. GC-C expressed on the surface of enterocytes serves as the receptor for the endogenous ligands uroguanylin and guanylin,
or ST produced by enterotoxigenic E. coli. Linaclotide, an ST peptide mimic, also binds to GC-C. Ligand binding increases intracellular levels of cGMP. Cyclic GMP activates
cGMP-dependent protein kinase II (PKGII) and inhibits the activity of the cAMP-phosphodiesterase PDE3, thereby cross-activating cAMP-dependent protein kinase (PKA).
PKGII and PKA phosphorylate the cystic ﬁbrosis transmembrane conductance regulator (CFTR), increasing its chloride-secreting activity. Cyclic GMP also enhances duodenal
bicarbonate secretion in a CFTR-dependent manner, and inhibits NHE3. These processes maintain ﬂuid and ion homeostasis. Cyclic GMP also directly activates cyclic
nucleotide gated channels (CNG) leading to Ca2+ inﬂux. Elevated intracellular Ca2+ levels bind to calcium sensing receptors (CaRs), resulting in cell differentiation and
migration. GC-C signaling is terminated by hydrolysis of cGMP–GMP by a cGMP-dependent phosphodiesterase, PDE5. Cyclic GMP production by GC-C is inhibited by c-src
mediated phosphorylation of a speciﬁc tyrosine residue in the guanylyl cyclase domain of GC-C.
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to be modulated by GC-C activity. Thus, in GC-C knock-out mice, an
increased activity of Akt (protein kinase B) was observed, resulting
in accelerated cell proliferation, which could be reversed by the
administration of cGMP [39]. In human colonic cell lines, activation
of GC-C resulted in changes in the expression of genes that are in-
volved in the Akt signaling pathway, suggesting that GC-C could
prevent intestinal tumour formation by inhibiting Akt signaling
[39]. It is not readily apparent at this time whether calcium inﬂux
and/or lower Akt activity are principally responsible for mediating
the cytostatic effects of activated GC-C. It is equally likely that the
main driving force for inducing colon cell cytostasis may involve
other signaling molecules that are operative under a particular
intestinal milieu, and such studies are awaited.
It is important to note that the GC-C expression is retained in co-
lon tumours, and therefore GC-C expression can be used as amarker
to diagnose metastatic colon cancer [42]. However, expression of
uroguanylin and guanylin is often lost in colorectal cancer progres-
sion [43]. Therefore, the anti-proliferative activity ofGC-C couldper-
haps be restored by administration of ST peptide analogs such as
linaclotide, or by the elevation of intracellular cGMP following inhi-
bition of cyclic nucleotide phosphodiesterases such as PDE5 [44].
A characteristic feature of most colorectal cancers is the high
activity of c-src tyrosine kinase seen in colon carcinoma cells
[45]. We have demonstrated that GC-C is regulated by c-src med-
iated inhibitory phosphorylation of a speciﬁc tyrosine residue in
GC-C. Consequently, the addition of ligands of GC-C to colonic can-
cer cells that contain elevated levels of active c-src does not result
in an increase in intracellular cGMP [46], and therefore would pre-
vent anti-proliferative signaling mediated by GC-C. Thus, a combi-
natorial therapy of c-src inhibitors, such as dasatinib [47], which is
in phase-2 clinical trials for the treatment of colorectal cancer,
along with activators of GC-C, such as linaclotide, may be an effec-
tive regime in the treatment of colon cancers.4. Roles of GC-C and cGMP in intestinal inﬂammation
Inﬂammatory bowel disease (IBD) is a chronic inﬂammatory
disorder and two main clinical presentations are Crohn’s disease
and ulcerative colitis [48]. Genetic factors, the host immune sys-
tem and the gut microbiome contribute to IBD, and disturbances
in the interaction between the intestinal epithelial cells and the
immune cells in the intestine appear to be responsible for these
syndromes. Therefore, any malfunctioning of the epithelial cells
could alter the responses of the immune cells in the gut, resulting
in inﬂammation.
Heightened inﬂammation, as a result of intestinal electrolyte
imbalance, is seen in infectious diarrheal disease and in patients
suffering from congenital chloride diarrhea [49]. Since GC-C regu-
lates ion secretion, it may be a mitigating factor in causing the
inﬂammation. Intestinal biopsies from patients suffering from
inﬂammatory bowel disease (IBD) showed down regulation of
the sodium-hydrogen ion exchanger 3 (NHE3) [50], and NHE3
knock-out mice overproduce inﬂammatory cytokines, and are
more susceptible to dextran sodium sulfate (DSS)-induced epithe-
lial injury [51]. Thus, the inhibition of NHE3 activity that is seen
following GC-C activation may contribute to the inﬂammation seen
in diarrheal disease. Suggestive of this is the observation that GC-C
knock-out mice, and to a lesser extent, guanylin knock-outs, show
reduced TNFb production and diminished apoptosis in the distal
colon following acute administration of DSS [52]. This may be cor-
related with the lower levels of cGMP in the intestinal epithelia of
GC-C and guanylin knock-out mice, which may have resulted in
hyper activation of NHE3, and therefore reduced inﬂammation.
Paradoxically, a disruption of the integrity of the intestinal bar-
rier is also seen in GC-C knock-out mice [53]. It is known that a dis-
ruption of epithelial barrier function can result in pathological
inﬂammatory responses as is seen in IBD. Moreover, down regula-
tion of guanylin and uroguanylin mRNA is seen in Crohn’s disease
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actually aggravate inﬂammation. It is therefore apparent that the
molecular bases, if any, of GC-C and cGMP-mediated regulation
of inﬂammation in the intestine, either via tight junction break-
down or altered pro-inﬂammatory cytokine expression in the
gut, are far from clear.
An interaction between intestinal microﬂora and host factors is
necessary for the development of intestinal inﬂammation, since in
the background of a genetic mutation in the host, speciﬁc viruses
or bacteria need to be present, along with environmental factors,
in the intestine in order to manifest disease [55]. We speculate that
perhaps ﬂuid and ion secretion regulated by GC-C could affect the
composition of the microbiome. Therefore, in GC-C knock-out
mice, the microbiota may differ from wild-type mice, and this
could contribute to the reduced inﬂammation that is seen, in spite
of tight junction disassembly.
5. GC-C and cGMP: of mice and men
As is usually the case for many genes, most of the studies that
relate to GC-C have to date been carried out in mouse models, or
in cell lines derived from human colorectal cancer tissue. What
appeared to be a lacuna was any report of a human disorder that
resulted from a mutation in the GC-C gene, GUCY2C. However, this
year, two studies appeared where point mutations in GUCY2Cwere
associated with human disease. The importance of these two
ﬁndings in emphasizing the role of GC-C in human intestinal phys-
iology cannot be overstated.
Familial diarrheas are severe and generally caused by recessive
mutations. Irritable bowel syndrome and Crohn’s disease are well
documented examples that show a genetic predisposition, and
are generally believed to be multifactorial, with a number of genet-
ic susceptible loci contributing to their occurrence in families.
Recently, a large Norwegian family was identiﬁed which demon-
strated a dominantly inherited, fully penetrant syndrome of fre-
quent diarrhea. Whole genome SNP-linkage based analysis and
exome sequencing identiﬁed a heterozygous mutation in GUCY2C
[14]. The effect of the Ser840 mutation to an Ile in GC-C was char-
acterized by heterologous expression of the mutant receptor. The
mutation interestingly resulted in a hyper-responsive form of
GC-C, whereby levels of cGMP produced by the mutant receptor
were 6–10-fold higher than observed for the wild type receptor,
at equivalent concentrations of ST peptide, uroguanylin or guany-
lin. What was intriguing was that while the afﬁnity of mutant
GC-C for ST or uroguanylin did not change, the EC50 for activation
by uroguanylin was signiﬁcantly lower in the mutant receptor in
comparison with the wild type receptor [14]. We therefore argued
that patients harboring this mutation would have elicited higher
intracellular levels of cGMP in the intestine in response to the
endogenous levels of uroguanylin or guanylin present in their gas-
trointestinal tract. Thus, this mutant GC-C was a gain-of-function
mutation, which would have resulted in over-activation of signal-
ing pathways that emanate from GC-C. One such pathwaymay reg-
ulate ﬂuid and ion secretion from the intestine, and involve
activation of CFTR and inhibition of NHE3, thus resulting in the
chronic and frequent episodes of diarrhea that these patients
experience.
What remained enigmatic, however, were the additional severe
symptoms reported by some patients [14]. Some individuals had
undergone laparotomy for suspected bowel obstruction, and ileal
inﬂammation, volvulus or adhesional bands, was conﬁrmed. Some
showed anatomical variants in the ileocaecal region, and needed to
undergo resection of the terminal ileum or caecum. In addition,
Crohn’s disease was observed in four of such patients. No emo-
tional disturbances, which could be a consequence of hyperactiveGC-C in neurons [35], were observed in any patients, and no one
showed any signs of leanness [33]. Clearly, the presence of over ac-
tive GC-C, and presumably elevated levels of cGMP, in these pa-
tients led to phenotypes that could not be predicted from results
seen in the GC-C knock-out mice.
The increased risk of inﬂammatory bowel disease in these pa-
tients could have been a consequence of enhanced inﬂammatory
cytokine production, as has been observed in NHE3 null mice
[50,56], and patients suffering from chloride diarrhea [49]. It could
be speculated that, in contrast to the GC-C knock-out mouse,
hyperactive GC-C could have led to a breakdown of intestinal bar-
rier function, resulting in the inﬂammation that is seen in these pa-
tients. Alternatively, as discussed above, the microbiota of these
patients may differ, consequent to the life-long incidence of diar-
rhea, resulting in an increased susceptibility to inﬂammation.
Following this ﬁrst report of a human disease correlated with a
gain-of-function mutation in the GUCY2C gene, inactivating muta-
tions of GC-C in a small Bedouin population were reported [15].
These patients also reported multiple disturbances, which led to
ileus, and blockage of the small intestine caused by thick mucoid
stools, presumably as a result of the lack of adequate ﬂuid being se-
creted via the GC-C signaling pathway. Here again, these results
contrast with mice data, where the GC-C knock-out mouse was
normal in terms of regular gastrointestinal function. Two inactivat-
ing mutations were reported in the Bedouin population, one which
was a substitution of Asp387 by a Gly residue, which reduced
cGMP production by  50% in the mutant receptor in contrast with
the wild type receptor. The second was an insertion of a single base
following Asn757, which would have truncated the receptor pro-
tein before the guanylyl cyclase domain, causing the mutant pro-
tein to be non-responsive to ligands of GC-C. The authors
speculate that these mutations would have rendered the carriers
resistant to ST-induced diarrhea, which could have been an advan-
tage to the desert dwelling Bedouins [15].
These to date remain the only two reports of mutations in GC-C
found in humans. Perhaps this once again emphasized the critical
requirement of the presence of an optimally functional GC-C in
the intestine, since neither its loss, nor its hyperactivity, can be tol-
erated in humans without severe consequences. In addition, in rec-
ognition of the differences that are known between the mouse and
the human immune system [57], it becomes important to realize
that perhaps not all of the reported roles of GC-C in the mouse
may be applicable in human physiology.
6. Future perspectives
Very important ﬁndings related to the roles of GC-C, and conse-
quently cGMP, have emerged over the past few years. Neverthe-
less, there are still a number of questions that remain. What are
the precise molecular mechanisms by which GC-C is able to aid
in colon cell cytostasis? Are there new players that may emerge
from a greater understanding of downstream effects of elevated
cGMP levels in the cell? What would be the consequences of a
knock-in hyperactivating mutation in GC-C in the mouse? Would
the phenotypes in mice mimic those seen in the Norwegian fam-
ily? If they did, this would provide a very good model to dissect
the underlying molecular mechanisms that contribute to the dis-
turbances seen in patients, thereby aiding in the development of
therapeutics for this disorder.
Cyclic GMP has always been considered the ‘poor cousin’ of
cAMP. Nevertheless, its signaling machinery is no less sophisti-
cated. A knock out of PKGII, the isoform predominantly expressed
in the intestine, resulted in mice being resistant to ST-mediated
ﬂuid accumulation, as might be expected [58]. However, an unex-
pected ﬁnding was that these mice showed skeletal abnormalities
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bone development [58,59]. PKGII knock-out mice were also defec-
tive in resetting the circadian clock, since PKG II activity was is re-
quired for the correct modulation of Per1 and Per2 levels [60].
Intriguingly, guanylin and uroguanylin show circadian regulation
in the rat intestine [61], thus suggesting a tantalizing link between
the intestine, behavior and circadian rhythm.
The multiple abnormalities seen in patients with altered GC-C
activity or expression reveal an underlying complexity in the pre-
cise roles of GC-C and its ligands in mediating intestinal homeosta-
sis. We anticipate that additional signaling outputs from GC-C may
depend on its apical or basolateral localization in the epithelial cell,
which could allow its association with speciﬁc signaling partners,
perhaps via direct protein–protein interaction. The multi-domain
nature of GC-C, and perhaps novel post-translational modiﬁcations
mediated via phosphorylation, may make GC-C amenable for such
interactions, as has been reported for c-src [16]. A large fraction of
GC-C is localized to the endoplasmic reticulum (ER), and glycosyl-
ated differently to the form that is found on the plasma membrane
[62,63]. The precise role of this ‘intracellular’ pool of GC-C is enig-
matic. Is it a fraction that is poised to be secreted to the plasma
membrane in a regulated manner? Or are there speciﬁc roles for
ER-localized GC-C, in that it may respond to stimuli other than
its known ligands, in a cGMP-independent manner? These are
some of the questions that we wish to address in the coming years.
Our motivation stems primarily from recent observations indicat-
ing the somewhat serious consequences of abnormal GC-C signal-
ing in the intestine, that suggest that much remains unknown
about this receptor, its ligands and cGMP signaling in the intestinal
epithelial cell.
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